However, in some studies, inhibition of MEK signaling alone with MEK162 is inadequate in treating EGFR-TKI resistant NSCLC cells, and negative feedback mechanisms in the PI3K pathway may be challenging when used independently [24]. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.